Role of oxaliplatin in the treatment of colorectal cancer

Therapeutics and Clinical Risk Management

Volumn 5, Issue 1, 2009, Pages 229-238

  Comella, Pasquale ^a   Casaretti, Rossana ^a   Sandomenico, Claudia ^a   Avallone, Antonio ^a   Franco, Luca ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Adjuvant treatment; Advanced disease; Bevacizumab; Cetuximab; Colorectal cancer; Fluorouracil; Leucovorin; Oxaliplatin

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; UFT;

ALOPECIA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSESTHESIA; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; LOADING DRUG DOSE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; ONCOGENE K RAS; OVERALL SURVIVAL; PARESTHESIA; POSTOPERATIVE CARE; PROGRESSION FREE SURVIVAL; REVIEW; STOMATITIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING; WILD TYPE;

EID: 77949450168     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/tcrm.s3583     Document Type: Review

References (59)

1. Rosenberg B, VanCamp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumour agents. Nature. 1969;26(222):385-386.
2. Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Marty M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol. 1990;25(4):299-303.
3. Diaz-Rubio E, Sastre J, Zaniboni A, et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study. Ann Oncol. 1998;9(1):105-118.
4. Machover D, Diaz-Rubio E, de Gramont A, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol. 1996;7(1):95-98.
5. Lévi F, Perpoint B, GarufiC, et al. Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer. 1993;29(9):1280-1284.
6. De Gramont A, Vignoud J, Tournigand C, et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer. 1997;33(2):214-219.
7. André T, Louvet C, Raymond E, Tournigand C, de Gramont A. Bimonthly high dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann Oncol. 1998;9(11): 1251-1253.
8. De Gramont A, Figer A, Seymour M, et al. Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer. J Clin Oncol. 2000;18(16):2938-2847.
9. Cunningham D, Sirohi B, Pluzanska A, et al. Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. Ann Oncol. Epub 2008 Oct 14. doi:10.1093/annonc/ mdn638.
10. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22(1):23-30.
11. Goldberg RM, Sargent DJ, Morton RF, et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: A North American Intergroup Trial. J Clin Oncol. 2006;24(21):3347-3353.
12. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR Study. J Clin Oncol. 2004;22(2):229-237.
13. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter Study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol. 2005;23(22):4866-4875.
14. Comella P, Massidda B, Filippelli G, et al. Oxaliplatin plus high dose folinic acid and 5-fluoruracil i.v. bolus (OXAFAFU) versus irinotecan plus high dose folinic acid and 5-fluoruracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: A Southern Italy Cooperative Oncology Group phase III trial. Ann Oncol. 2005;16(6):878-886.
15. Kalofonos HP, Aravantinos G, Kosmidis P, et al. Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. Ann Oncol. 2005;16(6):869-877.
16. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol. 2003;21(11):2059- 2069.
17. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001;19(8):2282-2292.
18. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19(21):4097-4106.
19. Twelves C. Capecitabine as first-line treatment in colorectal cancer: pooled data from two large, phase III trials. Capecitabine Colorectal Cancer Group. Eur J Cancer. 2002;38(Suppl 2):15-20.
20. Cassidy J, Tabernero J, Twelves CJ, et al. XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol. 2004;22(11):2084-2089.
21. Feliu J, Salud A, Escudero P, et al: XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer. 2006;94(7):969-975.
22. Comella P, Natale D, Farris A, et al. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal cancer. Final results of the Southern Italy Cooperative Oncology Group (SICOG) trial 0108. Cancer. 2005;104(2):282-289.
23. Porschen R, Arkenau H-T, Kubicka S, et al. Capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin: A randomized comparison in metastatic colorectal cancer - A final report of the AIO Colorectal Study Group. J Clin Oncol. 2007;25(27):4217-4223.
24. Díaz-Rubio E, Tabernero J, Gómez-Espa a J, et al. Phase III study of capecitabine plus oxaliplatin versus continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: Final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol. 2007;25(27):4224-4230.
25. Comella P, Massidda B, Filippelli G, et al. Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients. Results of the Southern Italy Cooperative oncology Group study 0401. J Cancer Res Clin Oncol. 2009;135(2):217-226.
26. Cassidy J, Clarke S, Díaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008;26(12):2006-2012.
27. Arkenau H-T, Arnold D, Cassidy J, et al. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: A pooled analysis of randomized trials. J Clin Oncol. 2008;26(36):5910-5917.
28. Rothenberg ML, Cox JV, Butts C, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol. 2008;19(10):1720-1726.
29. Meropol NJ, Rustum YM, Petrelli NJ, et al. A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer. Cancer Chemother Pharmacol. 1996;37(6):581-586.
30. González-Barón M, Feliu J, Garcia Girón C, et al. UFT modulated with leucovorin in advanced colorectal cancer: Oncopaz experience. Oncology. 1997;54(Suppl 1):24-29.
31. Saltz LB, Leichman CG, Young CW, et al. A fixed-ratio combination of uracil and ftorafur (UFT) with low dose leucovorin. Cancer. 1995;75(3):782-785.
32. Pazdur R, Lassere Y, Rhodes V, et al. Phase II study of uracil and tegafur plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal cancer. J Clin Oncol. 1994;12(11):2296-2300.
33. Carmichael J , Popiela T , Radstone D, et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2002;20(17):3617-3627.
34. Douillard J-Y, Hoff PM, Skillings JR, et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2002;20(17):3605-3616.
35. Bennouna J, Perrier H, Paillot B, et al. A phase II study of oral uracil/ftorafur (UFTs) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer. Br J Cancer. 2006;94(1):69-73.
36. Feliu J, Vicent JM, García-Girón C, et al. Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer. Br J Cancer. 2004;91(10):1758-1762.
37. Bajetta E, Di Bartolomeo M, Buzzoni R, et al. Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study. Br J Cancer. 2007;96(3):439-444.
38. Falcone A, Masi G, Allegrini G, et al. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol. 2002;20(19):4006-4014.
39. Falcone A, Ricci S, Brunetti, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25(13):1670-1676.
40. Souglakos J, Androulakis N, Syrigos K, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer. 2006;94(6):798-805.
41. Bajetta E, Celio L, Ferrario E, et al. Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. Ann Oncol. 2007;18(11):1810-1816.
42. Fornaro L, Masi G, Bursi S, et al. A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer. Cancer Chemother Pharmacol. 2008 Oct 7 [Epub ahead of print]. DOI 10.1007/s00280-008-0840-5.
43. Tabernero J, Van Cutsem E, Diaz-Rubio E, et al. Phase II Trial of Cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2007;25(33):5225-5232.
44. Souglakos J, Kalykaki A, Vamvakas L, et al. Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. Ann Oncol. 2007;18(2):305-310.
45. Borner M, Mingrone W, Koeberle D, et al. The impact of cetuximab on the capecitabine plus oxaliplatin (XELOX) combination in first-line treatment of metastatic colorectal cancer (MCC): A randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol. 2006; ASCO Annual Meeting Proceedings, Part I, 24(18S):3551.
46. Bokemeyer C, Bondarenko I, Makhson A, et al. Cetuximab plus 5FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. J Clin Oncol. 2007; ASCO Annual Meeting Proceedings, Part I, 25(18S):4035.
47. Bokemeyer, Bondarenko I, Hartmann JT, et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. J Clin Oncol. 2008; ASCO Annual Meeting Proceeding, Part I, 26(15S):4000.
48. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol. 2008;26(12):2013-2019.
49. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol. 2008;26(21):3523-3529.
50. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX-4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25(12):1539-1544.
51. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343-2351.
52. De Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. J Clin Oncol. 2007; ASCO Annual Meeting Proceeding, Part I, 25(15S):4007.
53. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J Clin Oncol. 2007;25(16):2198-2204.
54. Schmoll HJ, Tabernero J, Nowacki M, et al. Final safety findings from a randomized phase III trial of capecitabine + oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer. J Clin Oncol. 2006; ASCO Annual Meeting Proceedings, Part I, 24(18S):3569.
55. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Wolmark N. Initial safety report of NSABP C-08, a randomized phase III study of modified 5-fluorouracil (5-FU)/leucovorin (LCV) and oxaliplatin (OX) (mFOLFOX6) with or without bevacizumab (bev) in the adjuvant treatment of patients with stage II/III colon cancer. J Clin Oncol. 2008; ASCO Annual Meeting Proceeding, Part I, 26(15S):4006.
56. Gamelin L Boisdron-Celle M, Delva R. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res. 2004;15;10:4055-4061.
57. Nickevich DA, Grothey A, Sloan JA, et al. Effect of intravenous calcium and magnesium (IV CaMg) on oxaliplatin-induced sensory neurotoxicity (sNT) in adjuvant colon cancer: Results of the phase III placebo-controlled, double blind NCCTG trial N04c7. J Clin Oncol. 2008; ASCO Annual Meeting Proceeding, Part I, 26(15S):4009.
58. Grothey A, Hart LL, Rowland KM, et al. Intermittent oxaliplatin (oxali) and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONcePT trial. J Clin Oncol. 2008; ASCO Annual Meeting Proceeding, Part I, 26(15S):4010.
59. Cassidy J, Bjarnason GA, Hickish T, et al: Randomized double blind (DB) placebo (Plcb) controlled phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX-4) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC). J Clin Oncol. 2006; ASCO Annual Meeting Proceedings, Part I, 24(18S):3507.